A hubbub is brewing over the OTC analgesic lotion Joint-Ritis

February 2002

A hubbub is brewing over the OTC analgesic lotion Joint-Ritis.

It's the second most popular analgesic rub...after BenGay.

Joint-Ritis contains menthol 16% in a lanolin base. It also has glucosamine and chondroitin as INACTIVE ingredients.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

ibuprofen might reduce the benefit of taking low-dose aspirin
Dermatology new OTC Lotrimin that DOESN'T contain clotrimazole
Dermatology A hubbub is brewing over the OTC analgesic lotion Joint-Ritis
Dermatology Solaraze, a new topical gel for actinic keratoses
Hematology & Oncology Arimidex (anastrozole) is more effective than tamoxifen for EARLY breast cancer
Cardiology Advicor, the first combo drug for dyslipidemia
Cardiology whether to treat patients with "white-coat hypertension"
Infectious Diseases single-dose or three-day regimens of Zithromax (azithromycin) for acute otitis media in children
frequent use of triptans can actually EXACERBATE migraines
whether vitamin A causes hip fractures
ginkgo can cause seizures
Kineret (anakinra), a new biotech drug for rheumatoid arthritis
Women's Health women ask if they can insert their birth control pill VAGINALLY
Women's Health whether antibiotics reduce the efficacy of oral contraceptives
Now that Claritin is going off patent, Schering is coming out with Clarinex
Alzheimer's Disease NSAIDs reduce the risk of Alzheimer's
Hematology & Oncology triptorelin, Trelstar LA, for the palliative treatment of advanced prostate cancer
Practice chart of new drugs approved by the FDA in 2001